PREFER is developing recommendations for when and how patient preferences can contribute to industry, regulatory and HTA decision making throughout the medical product life cycle. We include patient stakeholders at every level of the project. This pdf booklet includes a list of our publications in chronological order (latest first), with abstracts and links to full text. The list was updated on 23 September 2021
Objectives: Patient preference information (PPI) is gaining recognition among the pharmaceutical in...
PREFER project developed a framework with points to for method selection that can be used by industr...
In order to develop the PREFER research agenda, a series of qualitative and quantitative assessments...
PREFER is developing recommendations for when and how patient preferences can contribute to industry...
Two key uses of patient preference information are to inform the choice of patient-relevant endpoint...
Industry, regulators, health technology assessment (HTA) bodies, and payers are exploring the use of...
Preference studies are becoming increasingly important within the medical product decision-making co...
Objectives: To investigate stakeholder perspectives on how patient preference studies (PPS) should b...
Background: The inclusion of patient preferences (PP) in the medical product life cycle is a topic o...
This document presents the take-home messages from the PREFER Recommendations, explaining when and w...
Objectives: To investigate stakeholder perspectives on how patient preference studies (PPS) should b...
Objectives: To investigate stakeholder perspectives on how patient preference studies (PPS) should b...
Patient preferences are critical for the successful development, regulation, and reimbursement of me...
Finding out what patients PREFER: Why, when and how to assess and use patient preferences in medical...
Industry, regulators, health technology assessment (HTA) bodies, and payers are exploring the use of...
Objectives: Patient preference information (PPI) is gaining recognition among the pharmaceutical in...
PREFER project developed a framework with points to for method selection that can be used by industr...
In order to develop the PREFER research agenda, a series of qualitative and quantitative assessments...
PREFER is developing recommendations for when and how patient preferences can contribute to industry...
Two key uses of patient preference information are to inform the choice of patient-relevant endpoint...
Industry, regulators, health technology assessment (HTA) bodies, and payers are exploring the use of...
Preference studies are becoming increasingly important within the medical product decision-making co...
Objectives: To investigate stakeholder perspectives on how patient preference studies (PPS) should b...
Background: The inclusion of patient preferences (PP) in the medical product life cycle is a topic o...
This document presents the take-home messages from the PREFER Recommendations, explaining when and w...
Objectives: To investigate stakeholder perspectives on how patient preference studies (PPS) should b...
Objectives: To investigate stakeholder perspectives on how patient preference studies (PPS) should b...
Patient preferences are critical for the successful development, regulation, and reimbursement of me...
Finding out what patients PREFER: Why, when and how to assess and use patient preferences in medical...
Industry, regulators, health technology assessment (HTA) bodies, and payers are exploring the use of...
Objectives: Patient preference information (PPI) is gaining recognition among the pharmaceutical in...
PREFER project developed a framework with points to for method selection that can be used by industr...
In order to develop the PREFER research agenda, a series of qualitative and quantitative assessments...